Therapeutic agents - Pharmacokinetics and pharmacodynamics

Reviews in Cardiovascular Medicine

Volumn 3, Issue SUPPL. 2, 2002, Pages

  Bell, William R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrin degradation products; Fibrinolytic system; Plasminogen activators; Plasminogen plasmin proteolytic enzyme system; Thrombolytic agents

Indexed keywords

ALTEPLASE; ANISTREPLASE; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOLYTIC AGENT; PLASMIN; PLASMINOGEN; PROUROKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE DERIVATIVE;

BLEEDING; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG BLOOD LEVEL; DRUG SPECIFICITY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; PATIENT SELECTION; PLASMINOGEN ACTIVATION; REVIEW; THROMBOEMBOLISM;

EID: 0036991615     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Tillet WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med. 1933;58:485-502.
2. Christensen LR, MacLeod CM. A proteolytic enzyme of serum: characterization, activation and reaction with inhibitors. J Gen Physiol. 1945;28:559-583.
3. Ratnoff OD. Studies on a proteolytic enzyme in human plasma, I: the probable identity of the enzymes activated by chloroform and by filtrates of cultures of beta hemolytic streptococci. J Exp Med. 1948;87:199-209.
4. Sherry S. The fibrinolytic activity of streptokinase activated human plasmin. J Clin Invest. 1954;33:1054-1063.
5. Fletcher AP, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man, I: induction and effects. J Clin Invest. 1959;38:1096-1110.
6. Johnson AJ, McCarty WR. The lysis of artificially induced intravascular clost in man by intravenous infusions of streptokinase. J Clin Invest. 1959;38:1627-1643.
7. Taylor FB Jr, Botts J. Purification and characterization of streptokinase with studies of streptokinase activation of plasminogen. Biochemistry. 1968;7:232-242.
8. Castellino FJ, Sodetz JM, Brockway WJ, Siefring GE Jr. Streptokinase. Methods Enzymol. 1976;45:244-257.
9. Morgan FJ, Henschen A. The structure of streptokinase, I: cyanogen bromide fragmentation, amino acid composition, and partial amino acid sequences. Biochim Biophys Acta. 1969;181:93-104.
10. Loch T, Bilinski T, Zakrzewski K. Studies on streptokinase: the conformation. Acta Biochim Pol. 1968;15:129-136.
11. McClintock DK, Bell PH. The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun. 1971;43:694-702.
12. Reddy KN, Markus G. Mechanism of activation of human plasminogen by streptokinase: presence of an active center in streptokinase-plasminogen complex. J Biol Chem. 1972;247:1683-1691.
13. McClintock DK, Englert ME, Dziobkowski C, et al. Two distinct pathways of the streptokinase-mediated activation of highly purified human plasminogen. Biochemistry. 1974;13:5334-5344.
14. Summaria L, Arzadon L, Bernabe P, Robbins KC. The interaction of streptokinase with human, cat, dog, and rabbit plasminogens: the fragmentation of streptokinase in the equimolar plasminogen-streptokinase complexes. J Biol Chem. 1974;249:4760-4769.
15. Brockway WJ, Castellino FJ. A characterization of native streptokinase and altered streptokinase isolated from a human plasminogen activator complex. Biochemistry. 1974;13:2063-2070.
16. Siefring GE Jr, Castellino FJ. Interaction of streptokinase with plasminogen: isolation and characterization of a streptokinase degradation product. J Biol Chem. 1976;251:3913-3920.
17. Chesterman CN, Cederholm-Williams, SA, Allington MJ, Sharp AA. The degradation of streptokinase during the production of plasminogen activator. Thromb Res Suppl. 1974;5:413-419.
18. Summaria L, Robbins KC. Isolation of a human plasmin-derived functionally active, light (B) chain capable of forming with streptokinase an equimolar light (B) chain-streptokinase complex with plasminogen activator activity. J Biol Chem. 1976;251:5810-5813.
19. Markus G, Evers JF, Hobika GH. Activator activities of the human plasminogen-streptokinase complex during its proteolytic conversion to the stable activator complexes. J Biol Chem. 1976;251:6495-6504.
20. Wohl RC, Summaria L, Arzadon L, Robbins KC. Steady state kinetics of activation of human and bovine plasminogens by streptokinase and its equimolar complexes with various activated forms of human plasminogen. J Biol Chem. 1978;253:1402-1407.
21. Robbins KC, Wohl RC, Summaria L. Plasmin and plasminogen activators: kinetics, and kinetics of plasminogen activaton. Ann N Y Acad Sci. 1981;370:588-591.
22. Takada A, Takada Y. Potentiation of the activation of Glu-plasminogen by streptokinase and urokinase in the presence of fibrinogen degradation products. Thromb Res Suppl. 1982;25:229-235.
23. Cederholm-Williams SA, De Cock F, Lijnen Hr, Collen D. Kinetics of the reactions between streptokinase, plasmin, and alpha2-antiplasmin. Eur J Biochem. 1979;100:125-132.
24. Urokinase pulmonary embolism trial: phase I results: a cooperative study. JAMA. 1970;214:2163-2172.
25. MacFarlane RG, Pilling J. Fibrinolytic activity of normal urine. Nature (London). 1947;159:779.
26. Williams JRB. The fibrinolytic activity of the urine. Br J Exp Pathol. 1951;32:530-537.
27. Sobel GW, Mohler SR, Jones NW, et al. Urokinase: an activator of plasma profibrinolysin extracted from urine. Am J Physiol. 1952;171:768-769.
28. Plough J, Kjeldgaard NO. Urokinase: an activator of plasminogen from human urine, I: isolation and properties. Biochim Biophys Acta. 1957;24:278-282.
29. Lesuk A, Terminiello L, Traver JH. Crystalline human urokinase: some properties. Science. 1965;147:880-882.
30. Sherry S, Lindemeyer RI, Fletcher AP, et al. Studies on enhanced fibrinolytic activity in man. J Clin Invest. 1959;38:810-822.
31. Burges RA, Brammer KW, Coombes JD. Molecular weight of urokinase. Nature (London). 1965;208:894.
32. White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry. 1966;5:2160-2169.
33. von Doleschel W. Isolierung einer dritten humanen urokinase. Wien Klin Wochenschr. 1975;87:282-284.
34. Murano G, Aronson DL. High and low molecular weight urokinase. Thromb Haemost. 1079;42:1006-1068.
35. Lesuk A, Terminiello L, Traver JH, et al. Biochemical and biophysical studies for human urokinase. Thromb Diath Haemorrh. 1967;18:293-294.
36. Soberano ME, Ong EB, Johnson AJ. The effects of inhibitors on the catalytic conversion of urokinase. Throm Res Suppl. 1976;9:675-681.
37. Holmerg L, Bladh B, Astedt B. Purification of urokinase by affinity chromatography. Biochim Biophys Acta. 1976;445:215-222.
38. Soberano ME, Ong EB, Johnson AJ, et al: Purification and characterization of two forms of urokinase. Biochim Biophys Acta. 1976;445:763-773.
39. McLellan WL, Vetterlein D, Roblin R. The glycoprotein nature of human plasminogen activators. FEBS Lett. 1980;115:181-184.
40. Landmann H, Markwardt F. Irreversible synthetische inhibitoren der urokinase [Irreversible synthetic inhibitors of urokinase]. Experientia. 1970;26:145-147.
41. Sherry S, Alkjaersig N, Fletcher AP. Assay of urokinase preparation with the synthetic substrate acetyl-L-lysine methyl ester. J Lab Clin Med. 1964;64:145-153.
42. Suyama T, Nishida M, Iga Y, et al. Difference in thrombolytic effect between higher and lower molecular weight forms of urokinase. Thromb Haemost. 1977;38:48.
43. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981;256:7035-7041.
44. Mackie M, Booth NA, Bennett B. Comparative studies on human activators of plasminogen. Br J Haematol. 1981;47:77-90.
45. Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res. 1980;18:815-830.
46. Bernik MB, Kwaan HC. Origin of fibrinolytic activity in cultures from human tissue. J Lab Clin Med. 1967;70:650-661.
47. Mullertz S. Plasminogen activator is spontaneously active human blood. Proc Soc Exp Biol Med. 1953;82:291-295.
48. Camiolo SM, Thorsen S, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin and plasmin. Proc Soc Exp Biol Med. 1971;138:277-280.
49. Thorsen S, Glas-Greenwalt P, Astrup T. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh. 1972;29:65-76.
50. Barlow GH, Lazer L. Characterization of the plasminogen activator isolated from human embryo kidney cells: comparison with urokinase. Thromb Res. 1972;1:201-208.
51. Bernik MB, Whiate WF, Oiler EP, et al. Immunologic identity of plasminogen activator in human urine, heart, blood vessels and tissue culture. J Lab Clin Med. 1974;84:546-558.
52. Tissot JD, Schneider P, Hauert J, et al. Isolation from human plasma of plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest. 1982;70:1320-1323.
53. Wijagaards G, Kluft C, Greenveld E. Demonstration of urokinase-related fibrinolytic activity in human plasma. Br J Haematol. 1982;51:165-169.
54. Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem. 1982;257:3276-3283.
55. Verstraete M. Biochemical and clinical aspects of thrombolysis. Semin Haematol. 1978;15:35-54.
56. Astedt B, Homberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature (London). 1976;261:595-597.
57. Wu MC, Adel AY. Comparative studies on urokinase and plasminogen activator from cultured pancreatic carcinoma. Int J Biochem. 1979;10:1001-1006.
58. Markus G, Takita H, Cumiolo SM, et al. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res. 1980;40:841-848.
59. Evers JL, Patel J, Madeja JM. Plasminogen activator activity and composition in human breast cancer. Cancer Res. 1982;42:219-226.
60. Lewis LJ. Plasminogen activator (urokinase) from cultured cells. Thomb Haemost. 1979;42:895-900.
61. Marder VJ, Donahoe JF, Bell WR, et al. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. J Lab Clin Med. 1978;92:721-729.
62. Gerard RD, Chien KR, Meidell RS. Molecular biology of tissue plasminogen activator and endogenous inhibitors. Mol Biol Med. 1986;3:449-457.
63. Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high molecular-weight form of urokinase from human urine. Arch Biochem Biophys. 1983;220:31-38.
64. Gurewich V, Pannell R. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood. 1987;69:769-772.
65. Lijnen HR, Van Hoef B, De Cock F, Collen D. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood. 1989;73:1864-1872.
66. DeMunk GAW, Rijken DC. Fibrinolytic properties of single chain urokinase-type plasminogen activator (pro-urokinase). Fibrinolysis. 1990;4:1-9.
67. Smith RA, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature. 1981;290:505-508.
68. Ferres H. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex. Drugs. 1987;33(suppl 3):33-50.
69. Crabbe SJ, Grimm AM, Hopkins LE. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy. Pharmacotherapy. 1990;10:115-126.
70. Weitz JI, Cruickshank MK, Thong B, et al. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest. 1988;82:1700-1707.
71. Topol EJ, Bell WR, Weisfeldt ML. Coronary thrombolysis with recombinant tissue-type plasminogen activator: a hematologic and pharmacologic study. Ann Intern Med. 1985;103:837-843.
72. TIMI-Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-935.
73. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
74. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115:256-265.
75. Bell WR. Complications of thrombolytic therapy-bleeding and rethrombosis. In: Sherry S, Schroeder R, Kluft C, eds. Controversies in Coronary Thrombolysis. London, England: Current Med Lit Ltd; 1989:59-75.
76. Bennett WR, Yawn DH, Migliore PJ, et al. Activation of the complement system by recombinant tissue plasminogen activator. J Am Coll Cardiol. 1987;10:627-632.
77. Hajjar KA, Nacham RL. Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen: further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J Clint Invest. 1988;82:1769-1778.
78. Vaughan DE, Mendelsohn ME, Declerck PJ, et al. Characterization of the binding of human tissue-type plasminogen activator to platelets. J Biol Chem. 1989;264:15869-15874.